DUBLIN – Shares in AB Science SA dipped just 4.7 percent Tuesday on news that it was halting a phase III trial of its tyrosine kinase inhibitor (TKI), masitinib, in rheumatoid arthritis (RA) following a futility analysis, which showed the study's probability of success was below 50 percent.